Kinetin had a 50% oral bioavailability and exhibited satisfactory plasma PK in mice and rats and was ~80% bound to plasma proteins SARS-CoV-2-infected transgenic mice expressing human ACE2 treated with an oral dose of kinetin (140 mg/kg per day) exhibited a decrease in viral replication of the gamma variant, and reduced lung necrosis, hemorrhage and inflammation, and increased survival at plasma concentrations lower than those achieved and shown to be safe in clinical trials of kinetin in patients with familial dysautonomia [179,180]. The gene discussed is ACE2; the disease is Riley-Day syndrome.